{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000056","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.809760+00:00","generated_at":"2026-05-19T18:21:06.090875+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Intensity Therapeutics receives Nasdaq minimum bid price deficiency notice","bullets":["Nasdaq notified INTS on June 6, 2025 that bid price was below $1.00 for 30 consecutive business days.","Company has a 180-day grace period, until December 3, 2025, to regain compliance.","Compliance can be achieved if closing bid price is $1.00 or more for 10 consecutive business days.","If not compliant by deadline, INTS may seek a second grace period or consider a reverse stock split.","No immediate effect on listing or trading; stock continues on Nasdaq Capital Market under symbol INTS."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000056","json":"https://secwatch.observer/filing/0001567264-25-000056.json","markdown":"https://secwatch.observer/filing/0001567264-25-000056.md","text":"https://secwatch.observer/filing/0001567264-25-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000056/0001567264-25-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000056/intensity-20250606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T18:21:06.090875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f9c2b5af069f78b74222d81f0f523a52cfbd316","claim":"INTENSITY THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"June 6, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “INTS” at this time. In accordance with Nasdaq List","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000056/0001567264-25-000056-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}